AdvanCell is a vertically integrated radiopharmaceutical company developing a revolutionary cancer treatment called Targeted Alpha Therapy, providing new hope for patients with untreatable cancers.
AdvanCell’s pipeline is powered by innovative technology and a novel approach that ensures a reliable and scalable supply of alpha therapies to drive clinical development and guarantee commercial-scale supply.
The AdvanCell team has deep experience across all facets of radiopharmaceutical development. The team is delivering innovation across manufacturing technologies, drug discovery and strategic and accelerated global clinical development.
Philina is a seasoned biopharmaceutical executive with more than 20 years of experience and a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology.
Before joining AdvanCell, Dr Lee served as Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi). She was instrumental in shaping the company’s strategy and building its commercial infrastructure in oncology and mast cell disorders. Earlier in her career, she held senior roles at Algeta ASA, where she helped build the organization that successfully launched the first and only approved alpha therapy, Xofigo®, in collaboration with Bayer AG. She has also held leadership positions at Sanofi and Genzyme.
Dr Lee also served on the Board of Directors of radiopharmaceutical company Fusion Pharmaceuticals, prior to its acquisition by AstraZeneca.
She holds a BSc in Biochemistry from the University of Alberta and a PhD in Cell Biology from the Massachusetts Institute of Technology.
Andrew is the founder, former CEO, and currently serves as Managing Director, Australia. Prior to AdvanCell, Andrew led investment activities for Riverland Capital, a private investment firm, where as a founder and director he focused on investing in China.
Andrew is a director of G2 Therapies, a spinout from the Garvan Institute, and is a director of CGI Glass Lewis, the Australian affiliate of Glass Lewis, a corporate governance advisory firm. Andrew was a director and shareholder of Yuan Chuan Radio (sold to Shanghai-listed Orient Securities), ASX-listed Hostworks Group (sold to Broadcast Australia), amongst other listed and private companies.
Andrew began his career at Peregrine Investments in Hong Kong in 1997 and holds a Bachelor of Arts degree from University of California, Berkeley.
Andrew is an experienced investor in healthcare and is responsible for business development for AdvanCell and corporate activities for the Company.
A/Prof Simon Puttick is the Chief Scientific Officer at AdvanCell, where he leads the company’s isotope production, pipeline development, and translational science programs. Simon brings extensive experience in the field of radionuclide therapies, with a career dedicated to advancing the development of targeted radiopharmaceuticals.
Simon completed a PhD in Chemistry at the University of Nottingham in 2012, followed by postdoctoral and early career fellowship positions at the University of Cambridge and the University of Queensland from 2012 to 2018. During this time, he focused on the development of novel radionuclide therapies.
In 2018, Simon joined CSIRO to lead a translational research program in targeted alpha therapies, driving innovation in the design and application of next-generation radiotherapeutics.
Simon joined AdvanCell in 2021 to lead the company’s scientific direction and the advancement of its isotope production technology and radiopharmaceutical pipeline.
Anna is a board-certified diagnostic and interventional Radiologist and thought leader in radiopharmaceutical therapies. Anna brings extensive experience in accelerated global drug development, trial design innovation, radiobiology, molecular imaging, regulatory affairs and clinical practice.
Prior to joining AdvanCell, she led early-stage asset development at RayzeBio and served as a management consultant at McKinsey & Company, focusing on clinical development, portfolio strategy, and regulatory and operational excellence.
Anna holds an MD from RWTH Aachen University, a PhD from Maastricht University, and an MBA from RWTH Aachen University and Tsinghua University Beijing. She obtained significant clinical practice and research experience in Germany, the Netherlands, China, Australia and Stanford, USA, and has experience raising over $500M USD in Venture Capital, public capital (IPO), and non-dilutive capital.
Matthew joined from POINT Biopharma, where he was a Senior Vice President of Business Development. Matt is based in Boston and has over 30 years of experience in company business development and as a law firm partner. He has a wide range of experience relevant to business development and M&A strategy. Matt has also contributed to therapeutic discovery – including as an inventor on a number of pipeline programs in different companies. His deal sheet includes strategic partnerships and acquisitions involving Eli Lilly, Pfizer, GSK, BMS, Merck, Genentech/Roche, Moderna and Astellas amongst others.
François Gaudet is an experienced drug developer with 24 years of industry experience at Novartis, Johnson & Johnson and as a biotech CSO. At J&J (Oncology), François was the discovery leader of the multiple myeloma franchise. His research group engineered and advanced several drugs to clinical trials, including two from inception to approval: TECVAYLI and TALVEY (both first-in-class). He is a co-inventor for both approved drugs. François conducted his PhD graduate work at the Whitehead Institute at the Massachusetts Institute of Technology in cancer epigenetics and mammalian development in Rudolf Jaenisch’s laboratory.
Justyna is a radiopharmaceutical manufacturing and operations executive with 16 years of experience leading the development, scale-up, and commercialization of clinical and commercial-stage radiopharmaceutical programs.
Before joining AdvanCell, Justyna served as Vice President and Site Head of Eli Lilly and Company’s Indianapolis radioligand therapy manufacturing site following Lilly’s acquisition of POINT Biopharma. She led the site’s transition into fully integrated commercial manufacturing operations, overseeing organizational expansion, operational readiness, regulatory approvals, and continued growth of commercial and clinical manufacturing capabilities.
Prior to Lilly, Justyna was Chief Operating Officer at POINT Biopharma, where she played a key role in scaling the organization and advancing manufacturing and commercialization capabilities for late-stage radiopharmaceutical programs. Earlier, as Vice President of Medical Isotope Development and Operations, she led isotope sourcing, supply chain strategy, and manufacturing operations supporting the company’s radiopharmaceutical pipeline.
Earlier in her career, Justyna held leadership positions at the Centre for Probe Development and Commercialization (CPDC), including Chief Executive Officer, where she led operational transformation initiatives and radiopharmaceutical development programs spanning early development through GMP clinical manufacturing.
Justyna holds an MSc. in Biochemistry from McMaster University.
Dayle has more than 20 years’ experience in strategic and operational roleswith in early and growth stage biotechnology companies where he has been involved in leading a broad range of functions over his career including, operational, quality, finance, IP, BD and corporate strategy functions. Dayle was COO of GammaDelta Therapeutics, a UK-based company focused on the development of γδ T cell immunotherapies, until its acquisition by Takeda in2022. Dayle was also a cofounder of Adaptate Biotherapeutics (acquired by Takeda in 2022).
Previously, Dayle’s roles have included COO of Kesios Therapeutics (anoncology drug development co.), investment manager at Touchstone Innovations where he led a number of early stage investments including Enterprise Therapeutics (potentiator programme acquired by Roche) and Storm Therapeutics, and was a cofounder and Commercial VP of Lectus Therapeutics (programmes acquired by UCB).
Dayle has a degree in Pharmacology (University of Leeds) and a PhD in Pharmacology (University of Oxford).
Andy has spent the last 25 years at the center of biotech and academic innovation in Cambridge, MA helping to build and scale purpose-driven organizations. Andy is passionate about building people-centric organizations where people are supported, challenged, and excited about their work in service of advancing the mission. He is practical by nature and focuses on designing “fit-for-purpose” structures and processes that are adaptable as the organization grows and support the needs of the business. With experience in building HR capabilities in several organizations, he has deep expertise in leading all aspects of HR.
Most recently, he was the Chief Administrative Officer for Relay Therapeutics, where he was responsible for leading the human resources and operations strategy for a rapidly growing company that was named the #1 best place to work in MA by the Boston Globe in 2022. Prior to Relay Therapeutics, he served for more than five years as the Chief People Officer at the Broad Institute of MIT and Harvard, where he was responsible for leading the human resources strategy for a community of more than 4,000 people, as well as leading space planning and design for Broad’s campus in Cambridge. Before that, he was Vice President of Human Resources at Merrimack Pharmaceuticals, head of Human Resources at Dyax Corp. and held roles in human resources at Harvard-affiliated hospitals. He is a member of the board of directors for the Northeast Human Resources Association and is a frequent speaker at industry conferences. He is also a trained leadership coach and supports leaders to successfully make the transition to broader, more complex leadership roles.
Andy lives in Belmont, MA with his wife and two daughters. When not shuttling the kids around to various sports, he spends lots of time running while competing in ultramarathons.
Kevin Kuan is a seasoned radiopharmaceutical executive with over a decade of experience in advancing targeted alpha/beta therapies and diagnostic agents. His expertise spans R&D, CMC, regulatory strategy, and GMP manufacturing, with a proven ability to navigate complex regulatory frameworks (FDA, TGA) and deliver clinical-stage assets.
As SVP of Technical Operations at AdvanCell, Kevin brings deep technical knowledge in radiochemistry and sterile manufacturing, paired with a leadership approach focused on building high-performing teams and operational excellence. He has successfully led facility upgrades, CDMO tech transfers, and global supply chain initiatives supporting clinical programs across the US and Australia.
Prior to AdvanCell, Kevin held senior roles at Clarity Pharmaceuticals and SAHMRI, where he contributed to IND submissions, QMS implementation, and the scale-up of radiopharmaceutical manufacturing. He holds a PhD in Organic Chemistry from the University of Adelaide and has co-authored more than 15 scientific publications.
William holds a PhD in Chemistry from the University of Adelaide and completed a post-doctoral fellowship at the University of Sydney where he developed novel radiopharmaceuticals. He joined AdvanCell in October 2021 as the Head of Chemistry.
Dr Tieu has over 11 years’ experience in drug development, project management and GMP manufacturing. Prior to joining AdvanCell Isotopes, Dr Tieu was the Senior Research Radiochemist at South Australian Health and Medical Research Institute, with responsibility for managing the development of over a dozen radiopharmaceutical and radioisotope products. His role also included scientific contribution to numerous chemistry, radiation and pre-clinical studies. During this period, he was part of a team who helped develop several radiopharmaceuticals including [18F]FDOPA, MK6240, [64Cu]Cu-peptides, [64Cu]Cu-ATSM, [89Zr]Zr-mAbs and production of various imaging isotopes including 68Ga, 89Zr, 45Ti and ²⁰³Pb.
Dr Tieu also has experience with manufacturing of 89Zr-mAbs for a first in human Phase 1 clinical trials. He has 26 publications and 2 patents with his work has been cited more than 443 times. His h-index is 13. Dr Tieu is a current member of the Australian and New Zealand Society of Nuclear Medicine.
Aaron heads AdvanCell’s legal and HR functions, and is also the Group Company Secretary. He has been working closely with AdvanCell since its inception and Series A raise back in late 2020.
Prior to AdvanCell, Aaron worked in corporate teams at leading international law firms Allen & Overy LLP in London, Herbert Smith Freehills in Sydney and MinterEllisonRuddWatts in Auckland, specialising in public and private mergers and acquisitions (including both PE and VC investments), public and private capital offerings, joint ventures and PPPs with government. Aaron also has over nine years General Counsel and executive experience at a high growth / dynamic global healthcare organisation in cancer-care provider GenesisCare. In all roles over the past 20 years, he has had a particular focus on the healthcare sector with businesses big and small.
Aaron is currently admitted as a barrister and solicitor of the Supreme Court of NSW, Australia and the High Court of New Zealand. He holds a Batchelor of Laws with Honours and a Batchelor of Commerce majoring in Finance & Marketing.
Paola has over 20 years’ experience in clinical operations and drug development, from early stage to phase IV, with focus on radioligand therapy (RLT) development in the US and globally.
Prior to AdvanCell, Paola was Director at Ariceum, where she provided strategic and clinical leadership for the early-stage alpha therapy IND, clinical protocol and trial set up.
Earlier, Paola was Sr Clinical Development and Operations Leader at Advanced Accelerator Applications (AAA) and Global Trial Director at Novartis (NVS), where she successfully led several RLT programs.
As first Clinical Operations employee at AAA, Paola built the global clinical operations department, set up and executed the NETTER-1 Phase III pivotal trial, leading to the successful IPO, marketing authorization of Lutathera® and subsequent acquisition of the firm. She further contributed operationally and strategically to IND and NDA submissions with the FDA and co-authored the NEJM publication.
At NVS, Paola contributed to the scale up of the RLT platform and was member of the ISRC committee in charge of protocols review and approval for the oncology division. She authored and executed the Lutathera® post-authorization protocols, including NETTER-2.
Paola earned her BSc and Ms in Biology at Milan University, Italy.
Andrew’s expertise lies in radiochemical processing and in the production and purification of radioisotopes. He has a particular interest in alpha emitting radionuclides that can be used in the field of targeted alpha therapy. Most recently he led, amongst other efforts, the fabrication of Ra-224/Pb-212 generators from Th-228 and the production of accelerator-produced Ac-225 at Oak Ridge National Laboratory for the US Department of Energy Isotope Program.
Sheruna completed a PhD in Medical Radiation Science from the University of Sydney in 2010 and has over 20 years’ experience in radiopharmaceutical manufacturing and registration. She has a deep understanding of the sterile manufacturing and regulatory requirements specifically in this area.
Sheruna’s professional career has spanned across clinical Nuclear Medicine, including research and development, facility design, sterile manufacturing and supply of radiopharmaceuticals in both the private and public health sectors.
She brings specific skills and background to AdvanCell in governance, risk management and radiopharmaceutical science (RPS).
Thomas completed a PhD in Biological Sciences and Biochemistry at the University of Tours in 2013 where his research was focused on the involvement of proteases in lung cancer progression. In 2014, Thomas moved to the Queensland University of Technology- Australian Prostate Cancer Research Centre as a Research Fellow to work on the roles of proteases in prostate cancer progression.
In 2018, Thomas started to work at the Mater Research Institute – University of Queensland as a Senior Research Officer focused on the development and preclinical validation of targeted therapies for pancreatic, ovarian and breast cancers. Thomas has been involved in various translational projects conducting to multiple high-impact publications, novel preclinical models and the progression of several agents to clinical testing.
Thomas joined AdvanCell as Preclinical Development Manager in October 2022 to push forward the preclinical development of the AdvanCell’s targeted alpha therapy portfolio.
Joana Brilhante is a radiopharmaceutical leader with over 15 years of international experience in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. Her expertise spans asset strategy, cross-functional drug development, molecular imaging, and global market launches across biotech, pharma, and academic settings.
She has held senior roles at Mariana Oncology, a Novartis Company, Bayer, and ANMI (now part of Telix), where she led the clinical and commercial advancement of oncology radiopharmaceuticals globally.
A trained nuclear medicine technologist, Joana holds an MSc in Clinical Research from the University of Liverpool (UK) and an MBA from Vlerick Business School (Belgium). This dual academic foundation enables her to bridge scientific innovation with strategic execution, driving end-to-end drug development from early research to global commercialization.
Stephen has over 25 years’ experience in clinical R&D within the academic sector along with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national science agency. He works closely with clinicians developing the next generation of molecular imaging, therapeutic and diagnostic platforms targeting oncology sector. Before joining AdvanCell, Prof Rose was director of a prestigious CSIRO Future Science Platform, a highly successful $35m research program with over 30 FTE scientific staff at the PhD level to drive innovation in the Medical Technologies and Pharmaceuticals sector. This included targeting the development of novel theranostic platforms for improved delivery of novel alpha radioligand therapies for difficult to treat cancers.
During this career, Prof Rose has made a significant contribution to obtaining competitive funding from various national medical research funding bodies (NHMRC, MRFF), state government R&D initiatives, the international pharmaceutical industry and private medical service providers. In terms of impact on health, he introduced to Australia a new PET tracer (F18-FEOBV) to measure cholinergic function in dementia patients and was instrumental in establishing clinical molecular imaging research program using MRI, F18-FDOPA and F18-FMISO PET to improve care pathways for patients with brain cancer. Prof Rose has played a major role of bringing new liquid biopsy diagnostic tests to the clinic including the development of NeuroLiB; the first epigenetic ccfDNA assay for detecting neural injury currently being validated through a prospective clinical trial. He was also instrumental in establishing a $5 million theranostics discovery R&D program with GenesisCare, the largest private providers of cancer care services in Australia. Prof Rose has published more than 240 manuscripts in international peer reviewed journals. In terms of general citation indices, his work has been cited 11900 times and his h-index is 52.
Aimee is a medicinal chemist with a decade of experience in the development of novel peptides for therapeutic applications. Dr. Horsfall brings her expertise in peptide chemistry and drug design, together with a passion for AdvanCell’s mission to change the course of cancer treatment, to lead AdvanCell’s ligand discovery and development pipeline for next generation targeted alpha-therapies.
Dr. Horsfall gained a PhD in chemistry from the University of Adelaide, focussed on the development of novel cyclic peptides as tools for interrogating biological processes and their potential use as pan-cancer therapeutics. Following a postdoctoral position at the University of Auckland, and a strong track record of peer-reviewed publications, Aimee joined AdvanCell in May 2023 to lead and grow their ligand development pipeline.
Dr. Megan Crumbaker is a medical oncologist. She earned her medical degree from the University of Sydney and completed a PhD in prostate cancer genomics at the University of New South Wales.
As a clinician-scientist at the Kinghorn Cancer Centre, St. Vincent’s Hospital Sydney, Dr. Crumbaker gained strong experience in cutting-edge clinical trials focusing on radioligand therapies and translational biomarkers. With a dedication to both research and patient care, Dr. Crumbaker is committed to advancing the field of oncology through innovative research and clinical trials.
Sze-Wan Li is a senior CMC executive with extensive experience in drug discovery and process development of radiopharmaceuticals and small-molecule kinase inhibitors. She has successfully guided multiple programs from early discovery through first-in-human studies to drug registration, consistently driving initiatives that deliver meaningful clinical impact and accelerate development timelines.
Prior to joining AdvanCell, Sze-Wan led late-phase radioligand programs at Eli Lilly, providing CMC and technical leadership in process scale-up and regulatory strategy for assets advancing toward commercialization. She also previously held leadership roles overseeing external GMP manufacturing and CMC regulatory activities at other organizations.
Earlier in her career, Sze-Wan spent over a decade in medicinal chemistry, advancing kinase inhibitor programs that contributed to first-in-human studies, multiple patent applications, and peer-reviewed publications.
Sze-Wan holds a Ph.D. in Organic Chemistry from the University of Toronto and an MBA in Management of Technology and Innovation from Toronto Metropolitan University.
Eugene Borrelli is a senior Quality executive with over 20 years’ experience in diagnostic and therapeutic radiopharmaceutical quality. He has successfully guided multiple programs from clinical supply to commercial distribution, ensuring that the programs meet all partner and regulatory needs.
Prior to joining AdvanCell, Eugene led both clinical and commercial Quality and Regulatory teams at SOFIE and Orano Med, as well as being both an RSO and an AU.
Eugene has been a key driver for quality and regulatory compliance throughout his career. When USP <797> was released governing sterile pharmaceutical compounding in the US, Eugene worked to design and implement the compliance program for a large PET network of radiopharmacies. Later, when the FDA released 21 CFR 212 to regulate the manufacture of PET radiopharmaceuticals, Eugene was again a lead member of the team, ensuring that drug supply was not interrupted during the transition.
He is excited to be part of the AdvanCell team.
Matthew is a medical strategist with expertise in both early and late-stage radiopharmaceutical development. Prior to joining AdvanCell, Matt spent the better part of a decade with Bayer Pharmaceuticals, holding positions within the US medical team and Global organization.
Over the past three years, he supported medical affairs activities for Radium-223, including overseeing the successful completion of key observational and real-world evidence studies and advancing ongoing collaborative trials. He also provided critical support and guidance for programs involving Actinium-225.
Matt holds a PhD from the University of California, Irvine. He subsequently completed a postdoctoral fellowship at the University of Michigan.
AdvanCell is privileged to have an experienced Board of Directors, with members who are leaders from venture capital, nuclear science and corporate governance.
Extensive board and business experience both in Pharmaceutical Biotech and major pharmaceutical companies. Three major exits in Biotech. Currently Chairman NeRRe Therapeutics, Chairman Nucana Plc, Chairman WalkSafe Ltd, Senior Advisor VCs, Consultant & Advisor to Boards and Executive teams in Biotech and Healthcare companies. Director of Amulet Consulting specialising in advisory roles with biotech.
Previously – President, CEO and board member of Algeta (leading oncology biotech, acquisition market cap $2.9 Billion) with R&D/manufacturing in Europe and co-promotion in the USA -successful exit in 2014. Chairman of Wilson Therapeutics which had a successful exit in 2018 for $855 million and KaNDy which had an exit of $875m in 2020.
International career spans CEO, country/business management, marketing, sales, medical/regulatory, manufacturing. Assignments include roles in the USA, UK, Italy, Switzerland and Scandinavia.
Philina is a seasoned biopharmaceutical executive with more than 20 years of experience and a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology.
Before joining AdvanCell, Dr Lee served as Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi). She was instrumental in shaping the company’s strategy and building its commercial infrastructure in oncology and mast cell disorders. Earlier in her career, she held senior roles at Algeta ASA, where she helped build the organization that successfully launched the first and only approved alpha therapy, Xofigo®, in collaboration with Bayer AG. She has also held leadership positions at Sanofi and Genzyme.
Dr Lee also served on the Board of Directors of radiopharmaceutical company Fusion Pharmaceuticals, prior to its acquisition by AstraZeneca.
She holds a BSc in Biochemistry from the University of Alberta and a PhD in Cell Biology from the Massachusetts Institute of Technology.
Andrew is the founder, former CEO, and currently serves as Managing Director, Australia. Prior to AdvanCell, Andrew led investment activities for Riverland Capital, a private investment firm, where as a founder and director he focused on investing in China.
Andrew is a director of G2 Therapies, a spinout from the Garvan Institute, and is a director of CGI Glass Lewis, the Australian affiliate of Glass Lewis, a corporate governance advisory firm. Andrew was a director and shareholder of Yuan Chuan Radio (sold to Shanghai-listed Orient Securities), ASX-listed Hostworks Group (sold to Broadcast Australia), amongst other listed and private companies.
Andrew began his career at Peregrine Investments in Hong Kong in 1997 and holds a Bachelor of Arts degree from University of California, Berkeley.
Andrew is an experienced investor in healthcare and is responsible for business development for AdvanCell and corporate activities for the Company.
Kevin is CEO at Ionetix Corporation. Prior to joining Ionetix in 2011, Mr. Cameron served as President of Glass, Lewis & Co., a leading independent corporate governance research firm which he co-founded in 2003. Prior to Glass Lewis, he served as General Counsel at Moxi Digital, a technology venture founded by Microsoft co-founder Paul Allen. Mr. Cameron previously served as General Counsel at NorthPoint Communications, a publicly-traded broadband telecommunications company acquired by AT&T. Before NorthPoint, he was an attorney with the corporate law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C. and served as a law clerk to the Hon. James L. Buckley of the United States Court of Appeals for the District of Columbia Circuit.
Mr. Cameron is a director of KERYX Biopharmaceuticals (NASD:KERX), a director of AvidBiotics, a former director of Reddy Ice, and was a founding board member of ProCure Treatment Centers, the leading provider of proton therapy treatment in the U.S. He earned a J.D. from the University of Chicago and a B.A. at McGill University.
Anthony Aiudi has been part of the investment team at Morningside Technology Advisory since 2020. He has experience providing operational and managerial oversight to early-stage biotechnology companies.
Anthony serves on the boards of several biotechnology companies across a broad spectrum of therapeutic areas. He has also facilitated company creation, completed multiple financings for private companies, and provided operational support for portfolio companies.
Anthony completed a Fellowship in Clinical Research at Cubist Pharmaceuticals and Northeastern University, where he was also adjunct faculty. He later was a clinical research scientist at Merck & Co. From late 2015-2020, he was a director at Stealth BioTherapeutics, where he led the clinical development for numerous rare disease programs through their global Phase 3 program and supported the company through its IPO.
Anthony received his Pharm.D. and MBA from the University of Rhode Island and an M.S. in finance from Northeastern University.
Jamil is a life science investor and company builder focused on advancing breakthrough science into transformational medicines for patients. Jamil joined SV Health Investors in January 2024 and is a Partner based in Boston. He works with founders, entrepreneurs, operators, and co-investors to establish and build new biotech startups, as well as fund and grow established private biotech companies across any stage of investment.
Jamil founded and operated several biotech startups as well as invested across therapeutic areas, stages of technology platforms/assets, and modalities. Over his career, Jamil has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), Kinaset Therapeutics (founding investor), Nido Biosciences (founder), RallyBio (NASDAQ: RLYB), Sage Therapeutics (NASDAQ: SAGE), and Transave Inhalation Therapeutics (merged with Insmed). Jamil brings a wealth of entrepreneurial and operational expertise from his time building companies like Sage Therapeutics and Nido Biosciences and founding several stealth biotech startups.
Jamil earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.
Bali Muralidhar, MD, PhD is Managing Partner, Chief Investment Officer and COO at Abingworth, a leading transatlantic life sciences investment firm. He has over 20 years professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice and teaching. He represents Abingworth on the boards of AdvanCell, Pathalys, Wugen and Ascend amongst others.
Prior to joining Abingworth, Bali was a senior partner at MVM Partners LLP in London where he completed investments in and served on the boards of several companies, both public and private. In 2018, Bali was named among Financial News’ Rising Stars in Private Equity, which celebrated 25 men and women under the age of 40 standing out in the European private equity industry. Before MVM, Bali was a member of Bain Capital’s healthcare deal team.
Bali obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers. He was also a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery and medicine.
Chris is a Principal at Sanofi Ventures, joining in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting, where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.
In addition to his role as a director on AdvanCell’s board, Chris represents Sanofi on the Boards of Sudo Biosciences, i2O Therapeutics and Minervax, and is an observer for Atalanta Therapeutics, Avilar Therapeutics, Matchpoint Therapeutics, and Nextpoint Therapeutics. Chris also serves on the Board of Trustees at Roger Williams University.
Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University.
Andrew Lam is Managing Director, Head of Biotech Private Equity at Ally Bridge Group, a leading global life science-dedicated investment group, where he leads private equity therapeutics investments. Dr. Lam has over 20 years of biopharma-focused experience across industry, equity research, and investment banking. He joined Ally Bridge Group in 2021 from Intercept Pharmaceuticals, where he was Senior Director of Business Development. Prior to joining Intercept, Dr. Lam served as Vice President of Healthcare Investment Banking at Jefferies, where he completed over 30 biopharma financing and M&A transactions, and as an equity research associate at BMO Capital and Canaccord Genuity, where he covered biotech. Before his time on Wall Street, Dr. Lam spent a decade in medical affairs at several biotech companies including Celgene and Shire. Dr. Lam currently serves on the boards of Epicripr Biotechnologies and Endeavor Bio Medicines. He is also on the board of New York BIO, the biotech trade association for the State of New York. He holds a PharmD from Long Island University and an MBA from Drexel University.
Nik Economopoulos, MBBS, MBA, is a Director at Alpha Wave Global LP, focusing on private biotech and medtech financings. Since joining Alpha Wave in 2023, he has served on the boards of several biotechnology and medical device companies spanning a range of therapeutic areas and modalities.
Nik brings over ten years of experience in business development, corporate strategy, M&A, and investing in the biopharma sector. Prior to Alpha Wave, he was a member of the Venture Investments team at Novo Holdings and a consultant at L.E.K. Consulting. Nik holds a medical degree from University College London and an MBA from London Business School.
AdvanCell is honored to be advised by leading experts in the fields of nuclear medicine, medical oncology, and prostate cancer.
Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 manuscripts and led or co-led multiple national and international clinical studies, including multiple phase III studies pivotal for FDA approval in prostate cancer (samarium-153 EDTMP, cabazitaxel, radium-223, and Lu-177-PSMA-617). In addition to therapeutic studies, he has long been involved with translational and scientific studies with prostate cancer patients. He has lectured widely, and at last count has given invited lectures in 33 countries.
After serving as a Professor of Medicine and Medical Director of the Tulane Cancer Center for 15 years, he moved to Mayo Clinic in April 2023 where he is now Professor of Medical Oncology, Chief of the Genitourinary Cancers Group, and Director of Radiopharmaceuticals.
Dr. Hermann is a well-known leader in the field of oncologic nuclear medicine. He currently acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen in Germany, Chair of the EANM Oncology & Theranostics Committee, and serves as a Section Editor of the Journal of Nuclear Medicine.
Ken’s earlier career found him as a Visiting Assistant Professor promoted to Associate Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles in addition to holding his position as Vice Chair of the Department of Nuclear Medicine at the Universitätsklinikum Würzburg. Ken holds a Doctorate Degree from Humboldt Universität Berlin and completed his residency in Nuclear Medicine at Klinikum rechts der Isar, Technische Universität München in addition to his MBA, which he received from the Universität Zürich, Switzerland in 2011.
Dr. Emmett is the Director of Theranostics and Nuclear Medicine at St. Vincent’s Hospital in Sydney, Australia, and a clinical researcher at the Garvan Institute of Medical Research. She is also a Professor of Medicine (conjoint)at the University of New South Wales. She underwent her medical training at Auckland University, New Zealand, physician training in Sydney, Australia, and postgraduate training in nuclear cardiology in Toronto, Canada. Her Doctorate of Medicine in nuclear cardiology was completed in 2014. Dr Emmett has a subspecialty interest in prostate cancer and has been Principal Investigator (or Co-PI) on multiple prospective phase 1-3imaging and therapy theranostics trials since 2014. Dr Emmett is focused on the clinical development of new theranostic agents, optimal combinations, and functional imaging biomarkers for better personalisation of treatment choices in theranostics.
Dr. Morris is a prostate cancer specialist, clinical investigator, full member, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.
He earned his medical degree from the Mount Sinai School of Medicine in New York and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Morris has led numerous clinical trials but has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on tumor and bone-directed radiopharmaceuticals for prostate cancer. He was part of the leadership team that developed Lu-177 PSMA-617, which is now FDA approved for men with advanced prostate cancer. He has a research focus interest in developing novel imaging technologies for metastatic prostate cancer and in credentialing imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and prostate-specific imaging technologies such as PSMA-directed PET imaging. In addition, he is the Medical Director of the Prostate Cancer Clinical Trials Consortium. He has long had an interest in novel methods of implementing prostate cancer clinical trials, and utilizing digital methods to reduce barriers to expertise, clinical care, and investigational studies.
Dr. Hope is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology and Biomedical Imaging at the University of California San Francisco. He serves as the Director of Molecular Therapy at UCSF and as Chief of Nuclear Medicine at the San Francisco VA Medical Center.
In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. Subsequently, he completed a residency in Diagnostic Radiology at UCSF, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford. Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He helped lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. Additionally he leads the PRRT program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.
Professor Shahneen Sandhu is an internationally recognised medical oncologist and clinician-scientist with an appointment at the Peter MacCallum Cancer Centre in Melbourne and Sir Peter MacCallum Department of Oncology at the University of Melbourne. Her research in prostate cancer and melanoma has focused on the co-development of novel therapeutics and biomarkers. Over her career, she has made significant contributions to developing new therapies and personalising therapies for prostate cancer and melanoma. Her research program comprises innovative clinical trials, biomarker and translational research that has established 7 new therapies for melanoma and prostate cancer. She has leadership roles in 6 clinical trials which evaluate the use of radionuclide therapy for metastatic castrate resistant prostate cancer. She runs several investigator-initiated trials including PRINCE (Pembrolizumab and 177Lu-PSMA),LuPARP (Olaparib and 177Lu-PSMA) and Evolution (Ipilimumab, Nivolumab and177Lu-PSMA) phase I/II trials.
Professor Michael Hofman is a nuclear medicine physician and physician-scientist at the Peter MacCallum Cancer Centre in Melbourne and Sir Peter MacCallum Department of Oncology at the University of Melbourne. He was named as Australia’s top researcher in the field of Nuclear Medicine, Radiotherapy & Molecular Imaging (“The Australian” Top 250 Researchers) in 2024 and 2025. At Peter Mac, he leads a theranostics Centre of Excellence, the PET/CT clinical program and is a member of the Research Leadership Group.
Prof. Hofman was an early pioneer of both PSMA PET/CT and PSMA theranostics, contributing to the evidence-base that has been transformative for improving outcomes for patients with prostate cancer. He has a strong track record having successfully led numerous clinical trials, from first-in-human trials of novel radiotracers to orchestrating complex multi-center randomised clinical trials.
His collaborative approach has brought together multi-disciplinary expertise from more than ten centres around Australia to conduct first-in-field trials resulting in seminal research published in high impact journal such as The Lancet. His research portfolio includes discovery research of new radiotracers, clinical trials (imaging and therapy) and using deep learning to develop new imaging biomarkers. He has delivered more than 250 talks in all 7 continents and has received numerous awards including the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Saul Hertz MD Award, a life-time achievement award recognising individuals who have made outstanding contributions to radionuclide therapy.
Dr. Kratochwil studied medicine at the University of Ulm in Germany. After graduating from medical school, his residency led him through the Departments of Nuclear Medicine of the University Hospital Ulm, Technical University Munich and Heidelberg University Hospital. He received his Doctors Degree (“18F-FLT for monitoring treatment response”) in 2008. Since 2010 he worked as a consultant and since 2013 as the supervising physician of the radionuclide ward of Heidelberg University Hospital.
His clinical and preclinical scientific interest is focused on targeted alpha-emitter therapy. Work related to 213Bi-Dotatoc was decorated with the SNM Nuclear Oncology Council Young Investigator Award and the RSNA Trainee Research Prize in 2011. Work related to 225Ac-PSMA617 with the EANM Marie Curie Award and the Therapy Award of the German society of Nuclear Medicine. Using ²⁰³Pb surrogate imaging, he explored PSMA-ligands with favorable characteristics for ²¹²Pb labeling. As a nuclear medicine professional and researcher, he already (co)authored approx. 180 peer-reviewed articles.
Professor Christopher Sweeney is the inaugural Director of the South Australian immunoGENomics Cancer Institute (SAIGENCI) at the University of Adelaide.
He received his medical degree from the University of Adelaide and completed an internship at the Royal Adelaide Hospital. Professor Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center (Wisconsin, USA) and a fellowship in hematology/oncology at Indiana University Medical Center (Indiana, USA), where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Professor Sweeney joined the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Harvard Medical School (Massachusetts, USA) in 2009. He was promoted to Full Professor at Harvard University in 2018 and returned to Australia in 2022. His primary research interest is drug discovery and development. His academic focus is primarily on the management of genitourinary malignancies, with a focus on prostate and testicular cancer.
Copyright © 2026 AdvanCell Pty Ltd. All Rights Reserved. Website by 
